

AMENDMENTS TO THE SPECIFICATION

Please amend Table 8 on page 41 of the specification to include sequence identification numbers, as follows.

Table 8. Tat-derived 15-mer peptides

Peptide	Aminoacid position	Amino acid sequence ^a	<u>SEQ ID NO:</u>
TC27	1-15	MEPVDPRLPFWKHPG	<u>33</u>
TC28	6-20	PRLEPWKHPGSQPKT	<u>34</u>
TC29	11-25	WKHPGSQPKTACTNC	<u>35</u>
TC30	16-30	SQPKTACTNCYCKKC	<u>36</u>
TC31	21-35	ACTNCYCKKCCFHCQ	<u>37</u>
TC32	26-40	YCKKCCFHCQVCFIT	<u>38</u>
TC33	31-45	CFHCQVCFITKALGI	<u>39</u>
TC34	36-50	VCFITKALGISYGRK	<u>40</u>
TC35	41-55	KALGISYGRKKRRQR	<u>41</u>
TC36	46-60	SYGRKKRRQRRPPQ	<u>42</u>
TC37	51-65	KRRQRRRPPQGSQTH	<u>43</u>
TC38	56-70	RRPPQGSQTHQVSL	<u>44</u>
TC39	61-75	GSQTHQVSLSKQPTS	<u>45</u>
TC40	66-80	QVSLSKQPTSQRGD	<u>46</u>
TC41	71-85	KQPTSQRGDPTGPK	<u>47</u>
TC42	76-90	QSRGDPTGPKEQKKK	<u>48</u>

^aPeptides were designed based on HIV-1 (BH10) Tat 102 aa long.

Please amend Table 11 on page 56 to include sequence identification numbers, as follows.

Table 11. Ovalbumin peptides

Peptide ID	Ovalbumin (aa)	Peptide sequence	Class I restriction	Reference	SEQ ID NO:
CFD	11-18	CFDVFKEL	H-2K(b)	Lipford et al. J. Immunol. 1993, 150:1212-1222	<u>50</u>
KVV	55-62	KVVRFDKL	H-2K(b)	Mo et al. J. Immunology. 2000, 164: 4003-4010	<u>51</u>
SII	257-264	SIINFEKL	H-2K(b)	Catipovic et al. J. Exp. Med. 1992, 176:1611-1618	<u>52</u>
OVA1	25-32	ENIFYCPI	H-2K(b)	Chen et al. J Exp. Med. 1994, 180:1471-1483	<u>53</u>
OVA2	107-114	AEERYPIL	H-2K(b)	Lipford et al. J. Immunol. 1993, 150: 1212-1222 Chen et al. J Exp. Med. 1994, 180:1471-1483	<u>54</u>
OVA3	176-183	NAIVFKGL	H-2K(b)	Lipford et al. J. Immunol. 1993, 150: 1212-1222 Chen et al. J Exp. Med. 1994, 180:1471-1483	<u>55</u>